6/14
02:26 am
egrx
Lifshitz Law PLLC Announces Investigations of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX), Driven Brands Holdings Inc. (NASDAQ:DRVN), Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), and Gristone bio, Inc. (NASDAQ:GRTS)
Low
Report
Lifshitz Law PLLC Announces Investigations of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX), Driven Brands Holdings Inc. (NASDAQ:DRVN), Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), and Gristone bio, Inc. (NASDAQ:GRTS)
6/14
01:16 am
egrx
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
6/6
11:14 am
egrx
Pneumonia Market and Epidemiology Insights 2018-2023 and Outlook 2024-2034 - Featuring Allergan/Pfizer, Merck Sharp and Dohme, Shionogi, Paratek Pharma, Nabriva Therapeutics, and More [Yahoo! Finance]
Medium
Report
Pneumonia Market and Epidemiology Insights 2018-2023 and Outlook 2024-2034 - Featuring Allergan/Pfizer, Merck Sharp and Dohme, Shionogi, Paratek Pharma, Nabriva Therapeutics, and More [Yahoo! Finance]
6/6
01:10 am
egrx
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
5/29
01:17 am
egrx
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
High
Report
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
5/22
09:14 am
egrx
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq [Yahoo! Finance]
High
Report
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq [Yahoo! Finance]
5/22
09:00 am
egrx
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
High
Report
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
5/21
03:05 am
egrx
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
5/14
12:09 am
egrx
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
4/30
08:00 am
egrx
Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual M
Low
Report
Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual M
4/15
07:10 am
egrx
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida [
High
Report
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida [
4/15
07:00 am
egrx
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
High
Report
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
4/12
04:23 pm
egrx
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K [Yahoo! Finance]
High
Report
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K [Yahoo! Finance]
4/12
04:05 pm
egrx
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K
High
Report
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K
4/5
01:00 pm
egrx
Lifshitz Law PLLC Announces Investigations of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX), ON Semiconductor Corporation (NASDAQ:ON), Mercury Systems, Inc. (NASDAQ:MRCY), and The Lovesac Company (NASDAQ:LOVE)
Low
Report
Lifshitz Law PLLC Announces Investigations of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX), ON Semiconductor Corporation (NASDAQ:ON), Mercury Systems, Inc. (NASDAQ:MRCY), and The Lovesac Company (NASDAQ:LOVE)